Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
Authors
Ferrer, LMalek, E
Bodet-Milin, C
Legouill, S
Prangère, T
Robu, D
Jeans, Steve
Tipping, Jill
Huglo, D
Carpentier, P
Illidge, Timothy M
Kraeber-Boderé, F
Morschhauser, F
Bardiès, M
Affiliation
ICO René Gauducheau, St Herblain, FranceIssue Date
2012-12
Metadata
Show full item recordAbstract
The aim of this study was to compare different dosimetric approaches on therapy naïve patients enrolled in a multicentre fractionated radioimmunotherapy trial, to determine which methodological approach correlates with bone marrow toxicity.Citation
Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. 2012, 56 (6):529-37 Q J Nucl Med Mol ImagingJournal
Quarterly Journal of Nuclear Medicine and Molecular ImagingPubMed ID
23358406Type
ArticleLanguage
enISSN
1824-4785Collections
Related articles
- High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
- Authors: Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, Papi S, Prisco G, Ferrucci PF, Martinelli G, Paganelli G
- Issue date: 2007 Nov
- Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
- Authors: Assié K, Dieudonné A, Gardin I, Buvat I, Tilly H, Vera P
- Issue date: 2008 Feb
- Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
- Authors: Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA
- Issue date: 2003 Mar
- Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
- Authors: Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ
- Issue date: 2003 Oct
- High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
- Authors: Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF
- Issue date: 2004 Jun